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The incidence of hepatocellular carcinoma (HCC) is 
increasing in  the United States. Although liver transplan- 
tation is an effective  means  of treating selected patients, 
pretransplantation  tumor progression  may preclude some 
patients from undergoing transplantation.  The aim  of this 
study is to determine the safety and efficacy  of percutane- 
ous radiofrequency thermal ablation (RFA) in 33 consec- 
utive patients with nonresectable HCC  and advanced cir- 
rhosis. Mean subject age was 57.2 f 10.6 years, mean 
Child-Turcotte-Pugh score  was  7.0 f 1.4, and mean  max- 
imal tumor diameter was 3.6 f 1.1 cm. Using contrast- 
enhanced computed tomography and magnetic  resonance 
imaging,  22 patients (66%) had a complete radiological 
response at 3 months post-RFA,  whereas 11 patients 
(33%) had an incomplete radiological  response. During 
follow-up, 18 patients (54%) experienced tumor progres- 
sion and 9 subjects underwent repeated ablation for either 
residual disease or  tumor progression. The overall actuar- 
ial patient survival rate of the 33 patients was 58% at  2 
years, whereas the transplantation-free patient survival 
rate was 34% at 2 years.  Fifteen  of 23  transplant candi- 
dates were successfully bridged to liver transplantation 
after a mean  post-RFA follow-up of  7.9 f 6. 7 months. 
The extent of tumor necrosis in  the explant varied, but no 
subjects had evidence of tumor seeding on post-RFA 
imaging, at liver transplantation, or in  the explant. The 
%year actuarial posttransplantation  patient survival rate 
was 85%.  Two patients have  developed posttransplanta- 
tion recurrence, and  both had microscopic  vascular  inva- 
sion in  their explants. In summary, our  data show that 
RFA  is a safe and effective treatment modality for patients 
with advanced cirrhosis and nonresectable HCC. 
Although the ability of RFA to prevent or delay tumor 
progression requires further prospective study, its favor- 
able safety profile and promising efficacy make it an 
attractive treatment  option  for liver transplant candidates 
with nonresectable HCC. (Liver Transpl 2002;8: 
I 165-1 174.) 
T he  incidence of hepatocellular  carcinoma (HCC) is increasing in the United States, with further 
increases projected over the  n xt two Treat- 
ment options for patients  who  present  with small 
tumors and preserved liver function include surgical 
resection and  tumor ablation.3-5 However,  the  majority 
of patients  present  with  either advanced cirrhosis 
and/or nonresectable HCC, with a median reported 
survival of only 6 months.6 Highly selected patients 
with  nonresectable HCC may undergo liver transplan- 
tation, with 1- and 3-year patient and graft survival 
rates of 90% and 70%, respectively.'-9 However, as the 
number of patients  awaiting  transplantation and time 
to transplantation increase, the  development of tumor 
enlargement, vascular invasion, and intrahepatic spread 
may preclude  many  patients  with HCC from  undergo- 
ing  curative  transplantation. As a result, safe and effec- 
tive means of treating and delaying the progression of 
HCC in liver transplant  candidates are urgently 
needed. 
Radiofrequency (RF) thermal ablation (RFA) is a 
novel means of treating  patients  with  both  metastatic 
and primary liver cancer.l0 The application of RF cur- 
rent  through  a  probe  inserted  into  the tumor leads to 
local tissue heating,  with  resultant tissue damage and 
coagulative necrosis. Results in  patients  with  a maximal 
tumor diameter of 3 cm have shown  prolonged disease- 
and recurrence-free survival.11,12 Advances in RFA 
equipment  and  technology also  have led to  encouraging 
results in  patients  with  a maximal tumor diameter  up  to 
5 ~ m . 1 3 , ~ ~  Although RFA requires puncture of the liver 
surface, the rate of bleeding and  other serious compli- 
cations  in  patients  with cirrhosis has been 10w.' l-~~  The 
primary  aim of this  study is to determine  the safety and 
efficacy of percutaneous RFA in 33 consecutive patients 
with  nonresectable HCC who were managed prospec- 
tively at  a single center. Our secondary aim is to deter- 
mine clinical and histological outcomes  in  a subset of 
15 patients  who  underwent liver transplantation  during 
study  observation. 
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Methods 
Patient  Selection 
Patients with known or suspected HCC referred for liver 
transplantation evaluation at the University of Michigan 
Medical  Center  (Ann  Arbor,  MI)  between  January  1996  and 
July 200 1 were  considered  for  possible  RFA. ll patients  were 
deemed to have nonresectable H C C  based on tumor size, 
location, or  the  presence  of  advanced  cirrhosis,  with  a  pro- 
jected life expectancy  of  at least 6 months.  Only  patients  with 
a  single tumor  nodule less than 6 cm in  maximal  diameter  or 
no  more  than  three  tumor  nodules,  each less than 5 cm  in 
maximal  diameter,  were  considered  for RFA. Exclusion  crite- 
ria  were  the  presence  of  known  vascular  invasion on pre-RFA 
imaging  studies,  known  extrahepatic  tumor,  subcapsular 
H C C ,  or uncorrectable  coagulopathy.  Histological  confirma- 
tion  of H C C  was performed  before  RFA  through  ultrasound- 
guided  biopsy,  when  possible.  Written  informed  consent was 
obtained  from all patients  before  RFA. 
Baseline  data  collection  included  subject  age, sex, cause  of 
liver disease, Child-Turcotte-Pugh (CTP) score, model for 
end-stage liver  disease (MELD) score,  serum  alphafetaprotein 
(AFP) level, and  Karnofsky  performance  status  (range, 0 
to  100).'5-'7  Multiphase  contrast-enhanced  computerized 
tomography (CT) or magnetic resonance imaging (MRI) 
with gadolinium was performed for tumor staging before 
treatment  in  29  of 33 patients,  whereas  an  ultrasound  exam- 
ination  of  the liver  was performed  in  the  remaining 4 subjects. 
RFA 
Percutaneous  RFA  was  performed  by  an  interventional  radi- 
ologist  under  real-time  ultrasound  guidance.  Local  anesthesia 
with  conscious  sedation  consisting  of  fentanyl  (Astra  USA, 
Westborough, MA) and midazolam (Versed; Roche Labs, 
Nutley,  NJ) was used  in  the  first 27 patients,  whereas  general 
anesthesia  was  used  in  the last 6 patients. In  25  patients,  RFA 
was delivered  using  a  model  500  RF  current  generator  and  a 
15-G RF probe,  model  30  (RITA  Medical  System,  Mountain 
View,  CA)  with  four  retractable  electrodes  that  were  deployed 
to a maximum diameter of 3 cm. In 8 patients, RFA was 
performed  using  a  model  1500  RF  generator  and  a 14-G RF 
probe,  model 70 Starburst  (RITA  Medical  System),  with  nine 
retractable  electrodes  that  were  deployed  to  a  maximum 
of 5 cm. 
Tumors  2  cm o r  less in  diameter  were  treated  with  a  single 
cycle of  thermal  ablation,  whereas  larger  tumors  were  treated 
with several overlapping ablations. Each ablation cycle was 
maintained  for  approximately 10 minutes,  with  a  target  tissue 
temperature of 95°C  to  100°C.  The  intrahepatic  portion of 
the  needle  track was ablated  during  removal  of  the  probe by 
using  the  tip  of  the  catheter  after  retraction  of  the  electrodes. 
Subjects  with  an  international  normalized  ratio  greater  than 
1.5 or platelet count less than  60,0001mL  were  administered 
blood  products  immediately  before  the  procedure.  Subjects 
were  either  admitted  to  the  hospital  for  overnight  observation 
or monitored  for  a  minimum  of 4 hours before discharge. 
Periprocedural  complications  were  prospectively  recorded. 
Radiological follow-up consisted of C T  or MRI  of  the 
liver within 6 weeks; at 3 ,6 ,9 ,   and 12 months;  and  then every 
6 months after RFA. Serum AFP levels, C T P  scores, and 
Karnofsky  scores also were assessed at  these visits. All subjects 
were followed up until death or last  available follow-up. 
Repeat  RFA was offered  to all patients  when  residual H C C  or 
new  tumor  nodules  were  detected  during  follow-up  imaging. 
The decision  to  repeat  ablation was determined  on  an  indi- 
vidual basis after  review of  tumor size and location,  previous 
response  to  therapy,  and  patient  desire  to be  retreated. 
Efficacy  Assessment 
Two radiologists  retrospectively  reviewed all scans  from CT 
and  MRI. Before treatment, all tumors were evaluated  radio- 
logically  for the  presence  of  vascular  enhancement,  maximal 
tumor diameter, and vascular invasion. The primary end 
point for radiological efficacy was defined by changes in 
tumor vascularity o n   C T  or  MRI  within 3 months  of RFA. A 
complete  response  was  defined as nonenhancement  or  a  thin 
peripheral  rim  of  enhancement  caused by an  inflammatory 
response  within 3 months  of  RFA.  An  incomplete  response 
was defined as persistent nodular enhancement within 3 
months  of  RFA.  Disease  progression was defined as new  sat- 
ellite  lesions  arising  within 2 cm  of  the  ablated  nodule or new 
nodules  that  arose  more  than 2 cm  from  the  original  lesion. 
Liver Transplant Recipients 
All liver transplant  recipients  underwent  surveillance  for 
H C C  recurrence  with  serum  AFP  testing  and  imaging  studies. 
Imaging  consisted  of  contrast-enhanced  chest  and  abdominal 
CT at 3, 6, 9, and 12 months and then every 6 months 
posttransplantation, as well as annual  bone  scans  and  chest 
radiographs.  Recurrence  of H C C  was established by histolog- 
ical confirmation  of  new or suspicious areas on  imaging  stud- 
ies. The primary immunosuppression regimen used in this 
cohort  of  patients  included  cyclosporine,  mycophenolate 
mofetil, and corticosteroids.  Steroid  therapy was withdrawn 
gradually between 6 and  12  months after liver transplanta- 
tion.  In  patients  with  proven HCC recurrence,  immunosup- 
pression  was  minimized,  and  adjuvant  therapy  was  pursued, 
when  possible. 
All biopsy  and  explant  specimen slides were reviewed  by a 
single  pathologist  U.K.G.).  Tumors  were  graded  according  to 
the  nuclear  grading  scheme  proposed by the  Armed Forces 
Institute  of  Pathology,  with  grade 1 representing  bland  ade- 
noma-like  features  and  grade 4 representing  marked  anapla- 
sia.I8 Amount  of  tumor necrosis was estimated on  a  percent- 
age  basis during  microscopic review. Additional  factors,  such 
as vascular  invasion,  satellite  lesions, and  margin  status, also 
were  evaluated. 
Data Analysis 
All statistical  analyses  were  performed  using  the SAS system 
(SAS Inc,  Cary,  NC).  Descriptive  statistics  of baseline demo- 
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graphics,  tumor  characteristics,  and  treatments  are  reported as 
mean ? SD, unless  indicated  otherwise.  Overall  patient  and 
transplantation-free survival, as well as time  to disease pro- 
gression, in the 33 patients were calculated using Kaplan- 
Meier  methods.  Posttransplantation  patient  survival  in  the 15 
liver transplant  recipients also  was calculated  using  Kaplan- 
Meier  methods. CTP  and   MELD scores  at  death  or last pre- 
transplantation  follow-up  were  compared  with  pretreatment 
values  using  two-tailed  Student’s  t-tests. To determine base- 
line  factors  associated  with overall survival,  transplantation- 
free survival, and time to disease progression, Cox propor- 
tional  hazards  models  were  used.  Because  of  the  small  sample 
size, the  following  pretreatment  covariates  were  selected  based 
on previously published studies: maximal tumor diameter, 
C T P  score,  serum  AFP level, Karnofsky  score,  tumor  grade, 
and  MELD score.  Each  covariate was entered  into  a  univariate 
Cox  model,  and  those  significant  at  the . 10-level or less were 
evaluated  in  a  multivariate  Cox  model.  Likelihood  ratio tests 
were  used to  determine  which  subset  of  covariates was to be 
included  in  the  final  multivariate  model.  Logistic  regression 
was  used to  determine  whether  tumor  diameter  and  baseline 
serum  AFP level were  associated  with  a  complete  radiological 
response  at 3 months. 
Results 
Patient  Population 
Thirty-one of 33 patients had biopsy-proven HCC, 
whereas 2  patients  underwent  nondiagnostic biopsies of 
suspicious hypervascular mass lesions. The majority of 
subjects were men (85%)  and white (91%),  and mean 
subject age was 57.2 t 10.6 years. Twenty-three 
patients (70%) were placed on  the liver transplantation 
waiting  list, and  15 patients have undergone  transplan- 
tation at last follow-up. Reasons for exclusion from 
transplantation were advanced age (4 patients), tumor 
size (2 patients), medical comorbidities (2 patients), 
and patient noncompliance (2 patients). The most 
common cause of liver  disease  was hepatitis C  (61%), 
and 4 of these patients  had disease that previously failed 
to respond to interferon  therapy. Twenty patients 
(61 %) reported  a  history of tobacco use. Two patients 
had  markedly elevated pretreatment  serum AFP levels 
(patient 1, 14,971 ng/mL; patient 5, 2,453 ng/mL), 
leading  to  a  median  pretreatment  serum AFP level of 33 
ng/dL  and  a mean  pretreatment  serum AFP level of 659 
ng/mL.  Mean  pretreatment CTP score was 7.0 ? 1.4, 
and  1  1 patients (33%) were Child’s class  A; 20 patients 
(6O%), class B; and  2 patients (6%), class C. 
Thirty-eight discrete HCC nodules were treated 
with RFA in these 33 patients. The majority of tumors 
were located  in  the  right  lobe of the liver, and mean 
maximum  diameter of tumor nodules was 3.6 L 1. l cm 
T d e  1. Baseline Feature of 33 Patiems with HCC 
Undergoing RFA 
No. of patients (Yo) 
Clinical  characteristics 
Men (Yo) 28 (85) 
Mean age  (yr) 57.2 5 10.6 
Ethnicity (Yo) 
Cause of cirrhosis 
White/Hispanic/Asian 30 (91)/2  (6)/1 (3) 
Hepatitis C 20 (61) 
Alcohol 7 (21) 
Cryptogenic 4 (12) 
Hepatitis B 1 (3) 
Autoimmune 1 (3) 
Mean CTP score 7.0 ? 1.4 
Class  A 11 (33) 
Class B 20 (60) 
Class C 2 (6) 
Mean MELD score 10.3 t 2.5 
Mean  Karnofsky  score 77 2 10 
Tumor features 
Tumor nodules 
l 29 (88) 
L 2  4 (12) 
Maximal  diameter  (cm) 3.6 ? 1.1 (1.5-6.0) 
Serum AFP (ng/mL) 659 & 2,608 (2-14,971) 
Elevated AFP (> 10 ng/mL) 26 (79) 
Tumor grade (I/II/III/IV) 4/ 1 O/ 13/4 
NOTE. Values  expressed  as  mean 5 SD (range) or number 
(percent). 
(Table 1). All patients  with pre-RFA imaging  studies 
had vascular enhancement,  but none of them showed 
evidence of vascular invasion. The RFA probe was suc- 
cessfully placed into all lesions under  ultrasound  guid- 
ance. In  25  subjects, RFA was performed using a  15-G 
probe  with  a maximal diameter of 3 cm, whereas in  8 
subjects,  a  14-G  probe  with  a maximal diameter of 5 cm 
was used. The ablation  procedure was terminated pre- 
maturely  in  patient 28 because of abdominal  discom- 
fort. 
Radiological Response 
Mean  duration of post-RFA follow-up to death  or last 
available  visit  was 21.1 t 13.0  months ( r  = 1.4  to 46.6; 
Table 2). At 3 months post-RFA, 22 patients (66%) 
had experienced a  complete radiological response, 
whereas 11  patients (33%) had  an  incomplete radiolog- 
ical response (Fig. 1). Increased maximal tumor diam- 
eter was associated with increased odds  for  an  incom- 
plete radiological response (odds  ratio, 2.5; 95% 
confidence  interval [CI] , 1.1  to  5.2; P = .03). However, 
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Table 2. Outcomes After RFA of HCC 
Maximum Time to Total 
Patient  Diameter  Radiologial  Nodules  Progression  Follow-Up 
No. (cm) Response  Ablated  Progression* (mo) (mol Outcome 
1 6 CR 1 1,2 5.0 9.9 D 
2 3.5 CR 1 - 
3 4.5 CR 1 - 
4  3 CR 1 - 
5  6 IR 1 1 1.2 2.1 D 
6 1.5 CR 1 2  4.1  38.2  A 
7 5 CR 1 1 2  4.1 38.0 AT 
9  4 CR 1 122 5.0 22.6 D 
10 2 CR 1 - 
11 3 CR 1 132 6.5 35.4  A 
12 3 CR 1 - 1.5 D 
13 4 IR 1 - 33.3 AT 
14 3 CR 1 1 12.9 42.9 A,T 
15  4.6 IR 1 1 2  1 .6 7.4 D 
16 2.5 CR 1 1 2  3.5 22.6 D 
17 5 IR 1 1 2  1.4 13.0  D 
18 4 CR 1 1,2 5.4 10.5 A 
19  2.6 CR 1 - - 26.9 A,T 
20 3.4 IR 1 __ - 28.0 AT 
21 5.1 CR 1 - - 22.3 AT 
22 5 IR 1 122 2.9 18.8 A 
23 3 CR 1  1  20.9 23.4 A 
24 4 IR 2  1 3.7 20.1 D 
25 3.2 IR 1 - 
26 2.5 IR 1  1 4.1 5.1  D 
27 3.8 CR 2  2 10.7  15.7 A 
28 2 CR 1 - - 16.3 A,T 
29 5.0  IR  1  2  1 .6 13.5 AT 
30 3.6 CR 1 - - 15.3 D,T 
31 3.5 IR  1 - - 11.4 A 
32 3.0 CR 1 - - 1.4 D 
33 2.8 CR 2 - 6.7 AT 
- 15.8 D,T 
- 46.6 A,T 
- 40.5 A,T 
8 3 CR 2 1 2  9.2 37.9 A 
- 36.1 A,T 
- 
- 
- 18.1 AT 
- 
Abbreviations: CR, complete  response; IR, incomplete  response; A, alive; D, dead; T, transplantation. 
*For progression; l = local, 2 = new. 
baseline serum AFP level and  tumor grade were not 
associated with radiological  response at 3 months. 
During post-RFA follow-up, 18 patients experi- 
enced disease progression, including 5 patients with 
local recurrence, 10 patients with local recurrence and 
new intrahepatic nodules, and 3 patients with  distinct 
new intrahepatic nodules located more than 2 cm  from 
the ablated tumor. Three of the 11 patients with an 
incomplete radiological response underwent repeated 
ablation  during follow-up, whereas the remainder was 
followed up conservatively. In  addition, 6 of  the 
patients with a complete radiological response at 3 
months underwent repeated ablation for tumor pro- 
gression during follow-up. 
Baseline  features  associated  with tumor progression on 
univariate  analysis  included tumor diameter,  serum AFP 
level, and pre-RFA MELD score (P < .lo). All three 
variables  remained  significant  when  jointly  entered into a 
multivariate Cox regression  model of tumor progression; 
baseline AFP (hazard ratio, 1.005; 95% CI, 1.002 to 
1.007; P = .OOl), tumor diameter  (hazard  ratio,  2.3; 95% 
CI, 1.1 to 4.9; P = .03), and baseline MELD score  (hazard 
ratio,  1.32; 95%  CI, 1.06 to 1.64; P = .02). More specif- 
ically, for  each 10-unit increase  in  baseline AFP level, there 
was a 5% increase in the likelihood  of tumor progression 
during follow-up when controlling for tumor diameter 
and pre-RFA MELD score.  Similarly,  for  each l-cm 
increase in pretreatment tumor diameter,  there was a two- 
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Figure 1. (A) A complete  radiological  response to RFA.  A49-year-old  man with  hepatitis  C virus cirrhosis  (patient 2) underwent 
RFA of a 3.5-cm HCC without  complications. At 9  months post-RFA, the tumor remained  necrotic,  with no vascular 
enhancement on contrast-enhanced CT. (B) An incomplete radiological  response to RFA. An 84-year-old man with 
cryptogenic cirrhosis (patient 22) underwent RFA of a  5-cm HCC without complications. At 3 months post-RF& there 
was persistent  nodular  enhancement (arrow) on the medial  side of the mass on contrast-enhanced CT, consistent with an 
incomplete response. 
fold  greater  likelihood f tumor progression when control- 
ling for baseline AFP level and pre-RFA MELD score. 
Last, for each l-point increase in MELD score, the hazard 
of disease progression  increased  by 32% when controlling 
for other variables. 
Clinical Outcomes and Survival 
Clinical outcomes of the 33 patients with HCC are 
shown in Figure 2. Fifteen of the 23 liver transplant 
candidates (65%) have undergone liver transplantation, 
Figure 2. Clinical outcomes 
of 33 consecutive patients Non-transplant 
undergoing RFA (23 liver 
transplantation candidates, 
10 non-transplantation can- 
didates). l \  
with a mean time  from  ablation to liver transplantation 
of 7.9 5 6.7 months (range, 0.6 to  22.6 months). Five 
liver transplant candidates died of liver failure after a 
mean post-RFA follow-up of 5.1 5 5.1 months,  and 3 
patients are still awaiting transplantation,  with a mean 
post-RFA follow-up of 21.4 5 14.7 months.  Among 
the  10 non-transplantation candidates, 5 patients have 
died of progressive  liver  disease, whereas 5 others  con- 
tinue to be followed up, with a mean post-RFA fol- 
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Figure 3. Actuarial  patient  and  transplantation-free sur- 
vival  after FWA in 33 patients with HCC (Kaplan-Meier 
plot). Overall survival, (-); transplant-free survival 
(-----). 
One-year actuarial overall and transplantation-free 
survival  rates  were 82% and 67%, respectively  (Fig. 3) .  
The only baseline feature associated with overall sur- 
vival  was maximum tumor diameter (hazard ratio, 1.74; 
95% CI, 1.02 to 2.98; P = .04). O n  univariate analysis, 
baseline MELD score,  Karnofsky  score, and serum AFP 
level  were significantly associated with  transplantation- 
free  survival (P < . lo).  However, on multivariate test- 
ing,  only baseline MELD score remained significantly 
associated with transplantation-free survival (hazard 
ratio, 1.7; 95% CI, 1.2 to 2.4; P = .004). 
Transplant  Recipients 
One-, 2-, and 3-year actuarial patient survival  rates  for 
the 15 transplant recipients  were 85% (data not 
shown). One liver transplant recipient (patient 2) died 
of intraoperative cardiac complications, and another 
patient  (no. 30) was withdrawn  from  support 10 days 
posttransplantation because of anoxic brain damage 
(Table 3) .  The remaining 13 transplant recipients  are 
alive, with a mean posttransplantation follow-up of 
26.9 ? 14.5 months (range, 5.5 to 42.1 months). 
Review of 14 explants showed variable amounts of 
tumor necrosis, with additional tumor nodules not 
detected on pretransplantation imaging in 6 patients 
(40%). Two subjects (13%) have  developed HCC 
recurrence posttransplantation. Patient 19 had portal 
vein invasion in his explant and developed biopsy- 
proven pulmonary metastases 6 months posttransplan- 
tation.  Patient 7 had portal vein  invasion and  an addi- 
tional 4-cm tumor nodule  in his explant that was not 
detected on pretransplantation imaging. Unfortu- 
nately, he developed  biopsy-proven HCC recurrence in 
his allograft 3.2 months posttransplantation. In both 
subjects, immunosuppression has been reduced, but 
neither has  been administered adjuvant chemotherapy; 
both remain alive at last follow-up. 
Safety 
Percutaneous RFA was associated with a low rate of 
periprocedural complications. Twenty-two subjects 
Table 3. Outcomes in 15 Liver  Transplant  Recipients who Underwent RFA Pretransplantation 
FoIIow-UP No. of Follow-Up 
Patient  pre-LT Tumor Explant  Necrosis Vascula   Post-LT  Recurrence 
No. (mo) Grade  Nodules (%) Invasion  (mol  (mol 
2  15.8 2 NA NA NA 0 - 
3 4.5 2 1 30 PV 42.1 - 
4  8.2 3  3 100 - 32.1 - 
7 9.3 3 2 75 PV 28.7 3.2 
10 11.0 2 1 70 - 25.1 - 
13  14.2 2 1 67 - 19.2 - 
14  22.6 3 1 75 __ 20.3 - 
19 3.9 3 1 25 PV 23.0 6.0 
20 0.7 2  2 10 - 27.3 - 
21 l .9 4 1 50 - 20.4 - 
25 0.6 3 1 90 - 17.5 - 
28  19.6 2  2 100 - 9.7 - 
29 3.0 2  2 80 - 10.5 - 
30  15.0 3  3 100 - 0.3 - 
33  1.1 2  2 50 - 5.5 - 
Abbreviations:  NA, not available; PV, portal  vein; LT, liver  transplantation. 
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were electively hospitalized  overnight  for  observation 
and discharged home  the following day, whereas the 
remaining  1  1  patients were treated as outpatients. Two 
patients (6%) had transient fever with malaise after 
RFA that resolved with  oral  antibiotic  therapy;  2  sub- 
jects (6%) developed an  intratumoral  hematoma  that 
resolved within 3 months;  and  1  subject  (3%)  reported 
short-term  abdominal  pain. No subject  had evidence of 
thermal  injury to adjacent  structures, and there was no 
evidence of needle-track  seeding on post-RFA imaging, 
at liver transplantation,  or  in  explant specimens. 
Although  there was a  slight increase in CTP  and MELD 
scores at last available pretransplantation visit com- 
pared  with  pre-RFA values, 76% of subjects  had  a fol- 
low-up CTP score within  1  point of their  pretreatment 
score. Specifically, among  the  15  patients  who  under- 
went transplantation, mean pretreatment CTP score 
did not significantly  change by the  time  of  transplanta- 
tion (7. l 5 1.4 v 7.1 k 1.6). Similarly, in  the  8  patients 
who  did  not  die  or  undergo  transplantation,  mean CTP 
score did  not significantly  change  (6.3 k 1.6 v 6.8 5 
1.5).  However, as expected,  there was a  trend  toward 
worsening CTP scores in  patients  who  died (7.5 k l .4 
v 9.3 k 2.8). 
Discussion 
As many as 40% of liver transplant recipients have 
evidence of HCC in  their e~plants.'9.~0 As the  waiting 
time  to liver transplantation increases, the  importance 
of having a safe and effective means of treating and 
delaying the progression of HCC in liver transplant 
candidates is apparent. Our data  show  that  percutane- 
ous RFA  is a safe and effective therapy  for  patients  with 
nonresectable HCC. Theoretical advantages of RFA 
over other  modalities are the localized nature of tissue 
destruction that can be completed in a single session 
and  the ability to repeat the treatment if residual or 
recurrent disease is detected.21  Potential risks associated 
with RFA include  the need to  puncture  the liver surface, 
with  attendant risks for tumor bleeding and seeding, 
and  the  potential to worsen global liver function.22 
At 3 months post-RFA, 66% of our patients had 
evidence of a  complete radiological response, whereas 
the remaining 33% had an incomplete radiological 
response. These radiological response rates are similar 
to those previously reported.'0~11,23,24 Possible explana- 
tions  for  an  incomplete response in  1  1  of our patients 
include  technical challenges posed by larger tumors and 
tumor location.22 Because multiple  overlapping spheres 
of tissue ablation are needed to treat tumors greater 
than  2 cm in maximal diameter,  it can  be difficult  to 
identify borders of large HCC tumor nodules  under 
ultrasound.l0>l2  Furthermore, large HCC tumor nod- 
ules are known to have a greater proclivity  for vascular 
invasion and high-grade histological characteristics 
associated with  a  poor response to thera~y.~5  In addi- 
tion,  the  enhanced vascularity of these large tumors can 
reduce the ability to maintain tissue temperatures at 
100°C  in all prongs of the RF probe.  Consistent  with 
these hypotheses, mean tumor diameter of patients 
with  an  incomplete radiological response in  our series 
was 4.2 cm compared  with 3.2 cm in  patients  with  a 
complete radiological response. Improved efficacy with 
laparoscopic RFA of larger tumors has been reported, 
presumably because of improved visualization and 
access to  the  tumor  nodule; however, this  approach also 
is associated with  a greater complication rate.26 
The optimal  time and means by which to define a 
post-RFA radiological response remain unclear. Imag- 
ing of the  tumor cavity within  1  or  2 weeks of ablation 
frequently shows an  enlarged,  inflammatory, hypervas- 
cular mass with  blood  elements. However, waiting  to 3 
months post-RFA may  allow the tumor  to progress  if it 
was incompletely treated. As a result, we and others 
recommend  that follow-up imaging be performed 4 to 
6 weeks post-RFA using either  contrast-enhanced CT 
or MRI.27,28 Other imaging  modalities,  such as semi- 
quantitative  estimation of tumor vascularity on MRI or 
color power Doppler  measurements of tumor vascular- 
ity with contrast agents, also may prove useful, but 
remain  in~estigational.~9-3' The extent of tumor necro- 
sis in explants of our  transplant recipients varied 
between 10% and  100% (mean, 60%).  The extent of 
coagulative necrosis after RFA  has been related to 
tumor size, tumor vascularity, success of the  initial abla- 
tion, and  duration of follow-~p.3~  The significant vari- 
ation  in these parameters  in  our  15  transplant recipi- 
ents, as  well  as the  learning curve associated with  a new 
treatment modality, may account for our observed 
results. 
Overall, RFA was  well tolerated  in  our  patients,  with 
a low rate of complications.  Although  some  patients 
were electively hospitalized for  observation, nearly all 
were discharged within 24 hours,  and  protracted 
abdominal pain and vascular thromboses were not 
observed, as reported  with  ethanol  ablation.28  Contrary 
to  other eports,  there was no evidence of thermal  injury 
to adjacent  structures  or tumor seeding on post-RFA 
imaging,  at liver transplantation,  or  in  the  explant spec- 
imens.23.33 The lack of tumor seeding may have been 
caused by our  ablation of the  intrahepatic  portion of the 
needle track before probe removal and exclusion of 
patients  with  subcapsular HCC. Although  the  majority 
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of these patients  had advanced liver  disease with ascites 
and coagulopathy, none of  the patients experienced an 
appreciable decline in global  liver function assessed by 
CTP scores, as reported with ~hemoembolization.3~,35 
During post-RFA follow-up, 54% of our patients 
showed either local or  intrahepatic  tumor progression 
(Table  2). The high rate of tumor progression in  our 
series and  others may relate to  the biological tendency 
for HCC tumors  to be multicentric  and spread within 
the liver.G Nine of the 18 patients with tumor progres- 
sion underwent repeated RFA, showing the need for 
close post-RFA surveillance. Although our  study was 
uncontrolled  and 45% of our patients underwent liver 
transplantation,  pretreatment predictors of tumor  pro- 
gression included tumor diameter, serum AFP level, 
and MELD score. These observations are consistent 
with previous studies showing a poor prognosis in 
patients with large tumors  and high serum AFP lev- 
els.6,36 If confirmed  in other prospective studies, these 
tumor characteristics may prove useful in  treating  indi- 
vidual patients and designing future trials of RFA in 
patients  with HCC. 
Overall and transplantation-free patient survival 
rates in  our series  were 82%  and 67% at 1 year and 58% 
and 34% at 2 years,  respectively  (Fig. 3). Although our 
study was small and  uncontrolled, these survival  rates 
are better than 1 -year  survival  rates recently reported in 
other large series of untreated HCC patient~.~.3"37 
Contrary  to  our expectations, pretreatment  serum AFP 
levels and severity of liver  disease  (i.e., CTP and MELD 
scores) were not associated with overall survival. The 
lack of  an association may have  been  caused by the small 
number of patients studied  and  the use of liver trans- 
plantation at varying times post-RFA in 15 patients. 
However, a significant association between pretreat- 
ment MELD score and transplantation-free survival 
was observed, confirming the importance  of liver  dis- 
ease severity in predicting survival in patients with 
HCC who  do  not undergo  transplantation. 
Percutaneous RFA  was a safe and effective bridge to 
liver transplantation  in 15 patients, with a mean pre- 
transplantation post-RFA follow-up of 8.8 2 7.3 
months. However, 5 of our liver transplant candidates 
died  of progressive liver failure while awaiting trans- 
plantation. Consistent with previous reports, 40% of 
liver transplant recipients were noted to have more 
tumor nodules in  the explant than visualized on pre- 
transplantation  imaging studies.7.19 However, only two 
patients have shown evidence of tumor recurrence post- 
transplantation.  Both  of these patients had evidence of 
vascular invasion in  their explant, previously  associated 
with  posttransplantation  rec~rrence.~5>38 Nonetheless, 
the 3-year patient survival  rate of 85% in  our transplant 
recipients  is  similar to  that reported in  other series of 
patients with HCC undergoing tran~plantation.T-~ 
Serial studies using MRI and magnetic resonance 
angiography every 3 months  to detect early portal vein 
involvement may prove worthwhile in liver transplant 
candidates with HCC; however, further studies are 
needed.3O 
In summary, our  data show that percutaneous RFA 
is  safe and appears to be an effective treatment modality 
for patients with nonresectable HCC and advanced 
liver  disease.  RFA  offers  several  advantages  over other 
ablative therapies in  that only a single  session is required 
and larger tumors can be treated. In a recent random- 
ized trial involving 86 European patients with HCC 
tumors less than 3 cm, RFA was associated with a 
greater radiological response rate than ethanol injec- 
tion.28 In contrast to microwave and laser-induced 
thermal ablation, the development of newer RF probes 
has  allowed  larger tumors to be  successfully  ablated.39.40 
In comparison to chemoembolization, RFA has not 
been  associated with a decline in global  liver function. 
Although 54% of our patients experienced tumor 
progression after a median follow-up of 4.1 months, 
RFA  has  allowed 15 of our  23 transplant candidates to 
undergo liver transplantation. Recent modeling studies 
suggest that percutaneous RFA may prove  cost-effective 
in patients with nonresectable HCC.41,42  The  apparent 
ability of RFA to prevent or delay tumor progression in 
our patients and its  excellent  safety  profile make it an 
attractive adjunctive therapy for selected liver trans- 
plant candidates with  known HCC. Although all our 
transplant candidates underwent RFA when organ allo- 
cation was  based on  CTP scores,  we anticipate that RFA 
will continue to serve as a useful  bridge to transplanta- 
tion  under the MELD allocation scherne.'7,43 
Additional large randomized controlled trials  using 
RFA are needed to improve our  understanding of the 
efficacy and durability of this promising treatment 
modality, as well as studies incorporating antiangiogen- 
esis agents and  other adjuvant therapies in  an attempt  to 
reduce the rate of post-RFA tumor progression and 
r e c ~ r r e n c e . ~ ~  
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